The first facility in Arizona to offer a noninvasive procedure for the treatment of a patient's symptomatic uterine tumors is scheduled to open mid October. ExAblate of Phoenix LLC will be available to local gynecologists to perform the nonsurgical treatment of uterine fibroids. The non-invasive procedure uses the ExAblate 2000 system, which received US FDA approval in October 2004.
"The ExAblate technology combines magnetic resonance imaging and focused ultrasound surgery (MRgFUS), which enables us to not only see the fibroid and surrounding organs in 3-D, but to destroy the targeted tumors inside the body without the need for traditional surgical incisions,” said Dr. Robert Gallai, M.D., FRCS(C), FACOG, medical director for ExAblate of Phoenix. “On average, patients return to normal activities in one to two days. Other surgical treatments for fibroids are invasive and can require several days of hospital stay and up to six weeks of recovery time."


Additional Content

News | Radiology Imaging

Nov. 2, 2026 — Neurophet and RapidAI have partnered to integrate Neurophet’s advanced neurodegenerative brain imaging ...

Time November 04, 2026
arrow
News | Radiology Imaging

Oct. 19, 2026 — Paradromics Inc. has announced a collaboration with Siemens Healthineers to develop an advanced ...

Time October 26, 2026
arrow
News | FDA

Oct.7, 2026 – MRI2CT Inc. has received FDA 510(k) clearance for NextMR, its AI powered imaging platform, for generating ...

Time October 07, 2026
arrow
News | Information Technology

October 6, 2026 – Clearsense has introduced a cloud-based medical image archive designed to reduce the cost of ...

Time October 07, 2026
arrow
News | PET-MRI

Sept. 29, 2026 —Yale New Haven Hospital has installed a state-of-the-art positron emission tomography/magnetic resonance ...

Time October 05, 2026
arrow
Subscribe Now